Compare Stocks

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.

Gemini Corporation, an integrated project construction company, focuses on energy and industrial facilities in Western Canada. It offers asset acquisition, environmental and regulatory support, engineering, fabrication, construction, maintenance, turnaround, decommissioning, reclamation, and remediation services, as well as project management services. The company serves oil and gas, heavy oil, oil sand, midstream and pipeline, hydrocarbon processing, power, and other industrial markets. Gemini Corporation was founded in 1982 and is headquartered in Calgary, Canada.

The iShares iBonds Dec 2030 Term Treasury ETF (IBTK) is an exchange-traded fund that is based on the ICE 2030 Maturity US Treasury index. The fund tracks a market value-weighted index of US Treasury bonds maturing between January and December 2030. The fund will terminate in December 2030. IBTK was launched on Jul 14, 2020 and is managed by BlackRock.